Podium to Practice: ESMO® 2025 – Melanoma: Phase 2 Study of Neoadjuvant Darovasertib
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
1602O – Enucleation prevention and vision preservation in primary uveal melanoma (UM): preliminary results from a phase 2 study of neoadjuvant darovasertib.
Studies/trials discussed:
1602O – Enucleation prevention and vision preservation in primary uveal melanoma (UM): preliminary results from a phase 2 study of neoadjuvant darovasertib.
199 Bay Street #4000
Toronto, ON M5L 1A9
©2025 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement.
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.